A phase 2 study of CBDCA + PEM + pembrolizumab in elderly (≥75 yrs) patients with advanced non-Sq, NSCLC.

Authors: Hiroaki Akamatsu, Kazuhiro Negoro, Ryota Ueda, Keita Nakaguchi, Yuhei Harutani, Eri Takase, Katsuyuki Furuta, Yusuke Murakami, Eriko Murakami, Atsushi Hayata, Ke Wan, Toshio Shimokawa, Kuninobu Kanai, Nobuyuki Yamamoto

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e20616

Source: Full article

---

Abstract

e20616